Ibnsina Pharma results, Fiscal year 2024
Net profit, assets, equity and cash flow for Fiscal year 2024, against the same period a year earlier, from the published financial statements.
Net profit615 millionEGP · +187.6% vs the same period a year earlier
Total assets28.64 billionEGP · +54.4% vs the same period a year earlier
Shareholders' equity2.03 billionEGP · +40.2% vs the same period a year earlier
Operating cash flow-1.1 billionEGP · −975.0% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Fiscal year 2024 was about 615 million EGP, up +187.6% from 214 million EGP in Fiscal year 2023.
- Total assets at the end of Fiscal year 2024 were about 28.64 billion EGP, and shareholders' equity about 2.03 billion EGP.
- Operating cash flow for Fiscal year 2024 was negative at 1.1 billion EGP.
Key lines against the same period a year earlier
This periodFiscal year 2023Change
Net profit615 million214 million+187.6%
Gross profit4.53 billion2.63 billion+72.3%
Total assets28.64 billion18.55 billion+54.4%
Total liabilities26.61 billion17.1 billion+55.6%
Shareholders' equity2.03 billion1.45 billion+40.2%
Total liabilities and equity28.64 billion18.55 billion+54.4%
Operating cash flow-1.1 billion126 million−975.0%
Investing cash flow-260 million-280 million+7.2%
Financing cash flow891 million744 million+19.9%
Net change in cash-295 million590 million−150.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy